摘要
目的探讨乳腺癌组织中微小RNA-155(miR-155)与人类表皮生长因子受体-3(HER-3)的表达,并分析其与临床资料的关系。方法选取2016年3月—2019年8月辽宁省本溪市中心医院收治的乳腺癌患者87例为研究对象。应用实时荧光定量PCR技术检测乳腺癌组织及癌旁组织中miR-155的表达量,应用免疫组织化学技术检测HER-3的表达情况,分析miR-155与HER-3的表达与临床资料之间的关系,分析miR-155与HER-3的相关性。结果乳腺癌组织中miR-155与HER-3的相对表达量均高于癌旁组织,差异均有高度统计学意义(均P<0.01)。不同肿瘤细胞分化程度、TNM分期及有无淋巴结转移的乳腺癌组织中miR-155、HER-3表达比较,差异有统计学意义(P<0.05)。乳腺癌组织中miR-155与HER-3的表达呈正相关(r=0.576,P<0.05)。结论乳腺癌组织中miR-155与HER-3的表达水平均升高,与肿瘤TNM分期、分化程度及淋巴结转移有关,有望成为指导乳腺癌诊断治疗的新的生物标志物。
Objective To investigate the expression of microRNA-155(miR-155)and human epidermal growth factor receptor-3(HER-3)in breast cancer tissues and to analyze their relationship with clinical data.Methods A total of 87 cases of breast cancer who treated in Benxi Central Hospital of Liaoning Province from March 2016 to August 2019 were selected as study objects.Quantitative real-time PCR was used to detect the expression of miR-155 in breast cancer tissues and adjacent tissues.Immunohistochemistry was used to detect the expression of HER-3.The expression of miR-155 and HER-3 and their relationship with clinical data were analyzed,and the correlation between miR-155 and HER-3 was analyzed.Results The relative expression levels of miR-155 and HER-3 in breast cancer tissues were higher than those in adjacent tissues,and the difference were highly statistically significant(all P<0.01).The expression of miR-155 and HER-3 in breast cancer tissues with different degree of tumor cell differentiation,TNM stage and lymph node metastasis had statistical significance(P<0.05).There was a positive correlation between miR-155 and HER-3 expression in breast cancer tissues(r=0.576,P<0.05).Conclusion The expression levels of miR-155 and HER-3 in breast cancer tissues are elevated,which are related to tumor TNM stage,differentiation degree and lymphatic metastasis,and are expected to become a new biomarker to guide the diagnosis and treatment of breast cancer.
作者
纪晓楠
李勇
李恩杰
JI Xiaonan;LI Yong;LI Enjie(Department of General Surgery,Benxi Central Hospital,Liaoning Province,Benxi117000,China)
出处
《中国医药导报》
CAS
2021年第8期94-97,F0004,共5页
China Medical Herald
基金
辽宁省自然科学基金计划重点项目(20170540503)。
